by Sue Robbins | Jul 30, 2020 | Migraine
Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period – Trial also...
by Sue Robbins | Jul 28, 2020 | Migraine
In patients with episodic migraine, erenumab provided sustained efficacy for the condition over the course of 1 year, according to new results from a study to evaluate the efficacy and safety of erenumab in migraine prevention (STRIVE), published in Neurology....
by Dr Robbins | Jul 28, 2020 | Migraine
I am doing a ½ hour medical radio segment the 1st and 3rd Tuesday of each month, 4pm central.I will talk about interesting medical topics of the week. We will have call-ins. 4:05 today, Central time..I will be a guest of Joan Esposito on her show. Joan is a terrific...
by Sue Robbins | Jul 26, 2020 | Migraine, Wellness
Nearly 7 in 10 American employed adults are now working from home all or some of the time in light of the COVID-19 pandemic, according to a May Gallup survey. With so many of us no longer reporting to the office every day, how can we use this new work setup to our...
by Sue Robbins | Jul 22, 2020 | Migraine
Positive genetic correlations of migraine with diastolic blood pressure (BP) and systolic BP exist, supporting the notions that diastolic BP plays a critical role in migraine susceptibility and BP and migraine share underlying biological mechanisms, according to...
by Sue Robbins | Jul 16, 2020 | Migraine
Insufficient response to triptans is associated with poor health-related quality of life (HRQoL) and lower work productivity in migraineurs compared with those who respond well to the medications, according to a study published in The Journal of Headache and Pain....
